Recombinant BatCoV RaTG13 Spike His-tag Protein, CF

Name: Recombinant BatCoV RaTG13 Spike His-tag Protein, CF
Brand: R&D Systems
SKU: 10660-CV

R&D Systems, Inc. a Bio-Techne Brand

Catalog # 10660-CV

Citations (1)

Product Datasheet / COA / SDS

Catalog #

Availability

Size / Price

Qty

Setting the standard in quality research reagents

Key Product Details

Source:	CHO
Accession #:	QHR63300.2
Applications:	Bioactivity

View Full Technical Details for Recombinant BatCoV RaTG13 Spike His-tag Protein, CF

Product Specifications for Recombinant BatCoV RaTG13 Spike His-tag Protein, CF

Source	Chinese Hamster Ovary cell line, CHO-derived batcov ratg13 Spike protein Val16-Pro12099 (Lys982Pro, Val983Pro), with a C-terminal 6-His tag
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin level	<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal sequence Analysis	Val 16
Predicted Molecular Mass	134 kDa
SDS-PAGE	154-175 kDa, under reducing conditions
Activity	Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 Fc Chimera (Catalog # 10544-ZN).

Scientific Data Examples for Recombinant BatCoV RaTG13 Spike His-tag Protein, CF

	Recombinant BatCoV RaTG13 Spike His-tag Protein Binding Activity. Recombinant BatCoV RaTG13 Spike His‑tag (Catalog # 10660-CV) binds Recombinant Human ACE-2 Fc Chimera (10544-ZN) in a functional ELISA.
	Recombinant BatCoV RaTG13 Spike His-tag Protein SDS-PAGE. 2 μg/lane of Recombinant BatCoV RaTG13 Spike His-tag (Catalog # 10660-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 154-175 kDa.

Formulation, Preparation and Storage

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10660-CV

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: Spike

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein(S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). SARS-CoV-2 Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-Cov-2, as with most coronaviruses, proteolytic cleavage of the S protein into two distinct peptides, S1 and S2 subunits, is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). Based on structural biology studies, the receptor binding domain (RBD), located in the C-terminal region of S1, can be oriented either in the up/standing or down/lying state (6). The standing state is associated with higher pathogenicity and both SARS-CoV-1 and MERS can access this state due to the flexibility in their respective RBDs. A similar two-state structure and flexibility is found in the SARS-Cov-2 RBD (7). SARS-Cov 2 is likely originated from Bat coronavirus RaTG13. Based on amino acid (aa) sequence homology, the Spike protein of RaTG13 shares 76% and 97% homology with Spike protein of SARS-CoV and SARS-CoV2, respectively. Despite high homology to SARS-COV2, five of the six key amino acids involved in ACE2 binding are different in RaTG13, leading to >1000 fold weaker binding to human ACE2 (8, 9). Before binding to the ACE2 receptor, structural analysis of the S1 trimer shows that only one of the three RBD domains in the trimeric structure is in the "up" conformation. This is an unstable and transient state that passes between trimeric subunits but is nevertheless an exposed state to be targeted for neutralizing antibody therapy (10). Polyclonal antibodies to the RBD of the SARS-CoV-2 protein have been shown to inhibit interaction with the ACE2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy (11). There is also promising work showing that the RBD may be used to detect presence of neutralizing antibodies present in a patient's bloodstream, consistent with developed immunity after exposure to the SARS-CoV-2 virus (12). Lastly, it has been demonstrated the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (13, 14).

Item	Value
References	Wu, F. et al. (2020) Nature 579:265. Tortorici, M.A. and D. Veesler (2019) Adv. Virus Res. 105:93. Bosch, B.J. et al. (2003). J. Virol. 77:8801. Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. 106:5871. Millet, J.K. and G. R. Whittaker (2015) Virus Res. 202:120. Yuan, Y. et al. (2017) Nat. Commun. 8:15092. Walls, A.C. et al. (2010) Cell 180:281. Malayia, J. et al. (2020) J Med. Virol. https://doi.org/10.1002/jmv.26261. Wrobel, A.G. et al. (2020) Nat. struct. Mol. Biol. https://doi.org/10.1038/s41594-020-0468-7. Ortega, J.T. et al. (2020) EXCLI J. 19:410. Wrapp, D. et al. (2020) Science 367:1260. Tai, W. et al. (2020) Cell. Mol. Immunol. https://doi.org/10.1016/j.it.2020.03.007. Okba, N. M. A. et al. (2020). Emerg. Infect. Dis. https://doi.org/10.3201/eid2607.200841. Wang, X. et al. (2020) https://doi.org/10.1038/s41423-020-0424-9. Wang, K. et al. (2020) bioRxiv https://doi.org/10.1101/2020.03.14.988345.
Long Name	Spike Protein
Entrez Gene IDs	918758 (HCoV-229E); 2943499 (HCoV-NL63); 39105218 (HCoV-OC43); 37616432 (MERS-CoV); 1489668 (SARS-CoV); 43740568 (SARS-CoV-2)
Alternate Names	2019-nCoV S Protein, 2019-nCoV Spike, COVID-19 Spike, E2, Human coronavirus spike glycoprotein, Peplomer protein, S Protein, S glycoprotein, SARS-COV-2 S protein, SARS-COV-2 Spike glycoprotein, SARS-CoV-2, SARSCOV2 Spike protein, Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein, Spike, Spike glycoprotein, surface glycoprotein

Citations for Recombinant BatCoV RaTG13 Spike His-tag Protein, CF (1)

Showing 1 - 1 of 1 citation Showing All

Filter By:

Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Recombinant BatCoV RaTG13 Spike His-tag Protein, CF include:

Species: Human
Sample Types: Serum/Plasma
Applications: ELISA

ES Geanes et al. (2022), Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination Scientific Reports, 12(1):6496.
PMID: 35444221

There are no citations that match your criteria.

Showing 1 - 1 of 1 citation Showing All

Product Documents for Recombinant BatCoV RaTG13 Spike His-tag Protein, CF

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS